Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606739 | 1.00 | POLB (0.50) | POLBALDH1A1HTTMAPTHPGD | |
| Hydrochloric Acid SCHEMBL2867268 | 0.97 | POLB (0.48) | POLBALDH1A1HTTMAPTHPGD | |
| Phosphonic Acid SCHEMBL5935310 | 0.87 | POLB (0.50) | POLBALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL15317985 | 0.81 | KDM4E (0.44) | POLBALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL13105724 | 0.80 | KIF11 (0.47) | POLBALDH1A1HTTMAPTCYP3A4 | |
| SCHEMBL4093853 | 0.80 | POLB (0.44) | POLBALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL1155655 | 0.80 | ALDH1A1 (0.53) | POLBALDH1A1HTTMAPTHPGD | |
| SCHEMBL30508518 | 0.80 | ALDH1A1 (0.53) | POLBALDH1A1HTTMAPTHPGD | |
| SCHEMBL9226189 | 0.80 | POLB (0.52) | POLBALDH1A1HTTMAPTHPGD | |
| SCHEMBL31549984 | 0.80 | ALDH1A1 (0.53) | POLBALDH1A1HTTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118119629-A | Nitrogen-containing heterocyclic compound and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117820287-A | Magnolol derivative, and preparation method and application thereof | 中国药科大学 | 2024-04-05 | — | — | CN | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| US-5300527-A | Administering anticholinergic agents for treating the memory dysfunction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-05 | — | — | US | disclosed |
| US-5177111-A | Analgesic | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-01-05 | — | — | US | disclosed |
| US-5136028-A | Red; colorfastness | CIBA-GEIGY CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0432719-A1 | Alkylamino- and alkylaminoalkyl diarylketones, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0428482-A1 | Reactive dyes, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1991-05-22 | — | — | EP | disclosed |
| US-5006563-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-04-09 | — | — | US | disclosed |
| US-4605766-A | REACTING AROMATIC AMINES WITH ETHERS IN PRESENCE OF CATALYST CONTAINING IRON OXIDE | ETHYL CORPORATION (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0148009-A2 | Process for the alkylation of aromatic amines and use of the products thereof | ETHYL CORPORATION (US) | 1985-07-10 | — | — | EP | disclosed |
| US-4374940-A | META-DIALKYL SUBSTITUTED TOLUIDINES, CURING | THE HENKEL CORPORATION (US) | 1983-02-22 | — | — | US | disclosed |
| US-4260545-A | REACTING AN ANILIDE WITH DIHALOMALEIC ANHYDRIDE, ANTIALLERGEN INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | POLB 4022/4885ALDH1A1 1370/4885HTT 4187/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | POLB 3996/4885ALDH1A1 1142/4885HTT 4306/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | POLB 639/4885ALDH1A1 4178/4885HTT 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.